Achieve Life Sciences (NASDAQ:ACHV) Announces Earnings Results

Achieve Life Sciences (NASDAQ:ACHV) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.06), Zacks reports.

Achieve Life Sciences Trading Down 2.5 %

Achieve Life Sciences stock opened at $3.06 on Tuesday. The company has a market cap of $105.23 million, a price-to-earnings ratio of -2.71 and a beta of 1.67. The firm has a 50-day moving average of $3.23 and a 200-day moving average of $4.06. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.78 and a quick ratio of 6.78. Achieve Life Sciences has a one year low of $2.82 and a one year high of $5.59.

Analyst Ratings Changes

A number of equities analysts recently weighed in on ACHV shares. RODMAN&RENSHAW raised shares of Achieve Life Sciences to a “strong-buy” rating in a research note on Thursday, November 14th. Rodman & Renshaw initiated coverage on Achieve Life Sciences in a research report on Thursday, November 14th. They set a “buy” rating and a $12.00 price objective for the company. Three research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Achieve Life Sciences has a consensus rating of “Buy” and an average target price of $15.75.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.